Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 10 (1) , 1957603
Abstract
Anti-PD1/PD-L1-directed immune checkpoint inhibitors are game changers in advanced non-small-cell lung cancer, but biomarkers are lacking. The aim of our study was to find clinically relevant biomarkers of the efficacy of ICI in non-squamous NSCLC. We conducted a retrospective study of patients receiving ICI for advanced non squamous NSCLC in two cohorts. For a subset of patients, RNAseq data were generated on tumor biopsy taken before ICI. The primary end point was progression-free survival under ICI. Secondary end point was overall survival from ICI initiation. In the cohort, we studied 231 patients. Clinico-pathological characteristics included KRAS mutant status (n = 88), TTF1-positive expression (n = 136), LIPI (Lung Immune Prognostic Index) score of 0 (n = 116). In our cohort, lack of TTF1 expression, LIPI score >0, line of treatment >1, and liver metastases were associated with poorer PFS. TTF1 and PD-L1 status could be used to stratify survival and improve the AUC for prediction of prognosis in comparison with the PD-L1 gold standard. Using an external cohort of 154 patients, we confirmed the independent prognostic role of TTF1. TTF1 expression and PD-L1 can be used to stratify risk and predict PFS and OS in patients treated with ICI for NS-NSCLC.Keywords
Funding Information
- no external funding
This publication has 58 references indexed in Scilit:
- A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumoursSurgical Oncology, 2014
- Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?Lung Cancer, 2014
- The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancerCancer Treatment Reviews, 2013
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant CancersClinical Cancer Research, 2012
- Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomasCancer, 2012
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung AdenocarcinomaJournal of Thoracic Oncology, 2011
- EGFR mutations and the terminal respiratory unitCancer and Metastasis Reviews, 2010
- Clinical Relevance of KRAS in Human CancersJournal of Biomedicine and Biotechnology, 2010
- Basal cells as stem cells of the mouse trachea and human airway epitheliumProceedings of the National Academy of Sciences, 2009
- LUNG CANCER PRENEOPLASIAAnnual Review of Pathology: Mechanisms of Disease, 2006